Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GALK1 | P51570 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 10/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5894034 | 0.80 | ACHE (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18434530 | 0.78 | KDM4E (0.53) | CA12CA1CA2CA4CA7 | |
| SCHEMBL28506437 | 0.78 | GPR84 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL99195 | 0.78 | KDM4E (0.42) | MAPTKDM4EKMT2APOLBRECQL | |
| SCHEMBL25608872 | 0.77 | MCHR1 (0.41) | CA12CA1CA2CA4CA7 | |
| SCHEMBL13313290 | 0.77 | ACHE (0.39) | MAPTKDM4ENSD2ACHEBCHE | |
| SCHEMBL5894494 | 0.77 | ACHE (0.44) | KMT2ATDP1L3MBTL1ACHEBCHE | |
| SCHEMBL13040647 | 0.76 | GPR84 (0.39) | CA12CA1CA2CA4CA7 | |
| SCHEMBL13406179 | 0.74 | CA1 (0.38) | CA12CA1CA2CA4CA7 | |
| SCHEMBL5352485 | 0.74 | MAPT (0.41) | MAPTKDM4EKMT2ATDP2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120035438-A | Use of 8-hydroxyquinoline derivatives | 江苏亚虹医药科技股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-118059101-A | Use of 8-hydroxyquinoline derivatives | 江苏亚虹医药科技股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117043141-A | 7-nitro-8-hydroxyquinoline derivative, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-102036678-A | Use of defensins against meningitis | NOVOZYMES AS | 2011-04-27 | — | — | CN | disclosed |
| EP-2278991-A1 | USE OF DEFENSINS AGAINST MENINGITIS | Novozymes Adenium Biotech A/S (DK) | 2011-02-02 | — | — | EP | disclosed |
| US-20090253629-A1 | USE OF DEFENSINS AGAINST MENINGITIS | NOVOZYMES A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| WO-2009121828-A1 | USE OF DEFENSINS AGAINST MENINGITIS | NOVOZYMES A/S (DK) | 2009-10-08 | — | — | WO | disclosed |
| US-20070191356-A1 | Pyridobenzoxazine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1712554-A1 | PYRIDOBENZOXAZINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-18 | — | — | EP | disclosed |
| EP-1017392-B1 | MEDICAMENT FORMULATION WITH A CONTROLLED RELEASE OF AN ACTIVE AGENT | BAYER AG (DE) | 2002-07-17 | — | — | EP | disclosed |
| US-6270799-B1 | 1-CYCLOPROPYL-7-((S,S)-2,8-DIAZABICYCLO(4.3.0)NON-8-YL)-6-FLUO RO-1, 4-DIHYDRO-8-METHOXY-4-OXO-3-QUINO-LONECARBOXYLIC ACID AND/OR PHARMACEUTICALLY TOLERABLE SALTS | BAYER AKTIENGESELLSCAHFT (DE) | 2001-08-07 | — | — | US | disclosed |
| EP-1017392-A1 | MEDICAMENT FORMULATION WITH A CONTROLLED RELEASE OF AN ACTIVE AGENT | Bayer Aktiengesellschaft (DE) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015172-A1 | MEDICAMENT FORMULATION WITH A CONTROLLED RELEASE OF AN ACTIVE AGENT | BAYER AKTIENGESELLSCHAFT (DE) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191356-A1 | Pyridobenzoxazine derivative | VIP, HAX1, CXXC5 | CA12 812/4885CA1 705/4885CA2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.